9805997-6
IPOS copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68, C07K 16/30, G01N 33/53 — A1

(11) International Publication Number: WO 98/00561

(43) International Publication Date: 8 January 1998 (08.01.98)

(21) International Application Number: PCT/GB97/01739

(22) International Filing Date: 30 June 1997 (30.06.97)

(30) Priority Data:
9613629.6 28 June 1996 (28.06.96) GB

(71) Applicant *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MARKHAM, Alexander, Fred [GB/GB]; West Riding Medical Research Trust, Molecular Medicine Unit, Clinical Sciences Building, St. James's University Hospital, Leeds LS2 9JT (GB). GUILLOU, Pierre, John [GB/GB]; West Riding Medical Research Trust, Molecular Medicine Unit, Clinical Sciences Building, St. James's University Hospital, Leeds LS9 7TF (GB).

(74) Agent: ZENECA PHARMACEUTICALS; Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: REG GENE EXPRESSION IN CANCER TISSUE

(57) Abstract

The invention relates to a marker for determining the tendency towards a cancerous condition and/or the aggressive nature of cancer tissue with a view to determining a prognosis and suitable course of action/treatment. More specifically, the invention concerns an investigation for products of the (*REG*) gene, i.e. the pancreatic protein lithostathine (*REG*) gene.